| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| ADMAADMA Biologics, Inc. | 4.16B | 17.50 | 21.60 | 65.15% | 42.87% | 48.57% | 2.64% | 0.24 |
| CVACCureVac N.V. | 1.05B | 4.66 | 6.47 | 8.96% | 37.93% | 33.02% | 7.95% | 0.06 |
| DWTXDogwood Therapeutics, Inc. | 83.24M | 2.80 | -0.22 | -49.37% | 0.24 | |||
| ALGSAligos Therapeutics, Inc. | 44.22M | 8.26 | -0.39 | -74.6% | -32.68% | -120.37% | ||
| INOInovio Pharmaceuticals, Inc. | 108.55M | 1.58 | -0.40 | -73.83% | -592.82% | -115.42% | 0.17 | |
| BRNSBarinthus Biotherapeutics plc | 29.81M | 0.73 | -0.47 | 17.66% | -408% | -89.73% | 0.09 | |
| COCPCocrystal Pharma, Inc. | 15.3M | 1.11 | -0.65 | -126.11% | 0.19 | |||
| KLRSKalaris Therapeutics Inc | 165.7M | 8.86 | -0.76 | -170.84% |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 40.57M | 35.37M | 42.22M | 30.48M | 4.11M | 7.41M | 1.77M | 10.26M | 832.01K | 217.76K |
| Revenue Growth % | 2.88% | -0.13% | 0.19% | -0.28% | -0.87% | 0.8% | -0.76% | 4.78% | -0.92% | -0.74% |
| Cost of Goods Sold | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| COGS % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | 40.57M | 35.37M | 42.22M | 30.48M | 4.11M | 7.41M | 1.77M | 10.26M | 832.01K | 217.76K |
| Gross Margin % | 1% | 1% | 1% | 1% | 1% | 1% | 1% | 1% | 1% | 1% |
| Gross Profit Growth % | 2.88% | -0.13% | 0.19% | -0.28% | -0.87% | 0.8% | -0.76% | 4.78% | -0.92% | -0.74% |
| Operating Expenses | 75.86M | 112.6M | 126.86M | 124.57M | 115.22M | 131.49M | 302.99M | 277.84M | 144.77M | 112.62M |
| OpEx % of Revenue | 1.87% | 3.18% | 3% | 4.09% | 28.02% | 17.74% | 170.72% | 27.07% | 174% | 517.17% |
| Selling, General & Admin | 18.06M | 23.89M | 28.29M | 29.32M | 27.2M | 37.25M | 53.75M | 90.19M | 47.58M | 37M |
| SG&A % of Revenue | 0.45% | 0.68% | 0.67% | 0.96% | 6.62% | 5.03% | 30.29% | 8.79% | 57.19% | 169.9% |
| Research & Development | 57.79M | 88.71M | 98.57M | 95.26M | 88.02M | 94.25M | 249.24M | 187.65M | 86.68M | 75.62M |
| R&D % of Revenue | 1.42% | 2.51% | 2.33% | 3.13% | 21.41% | 12.72% | 140.44% | 18.29% | 104.18% | 347.27% |
| Other Operating Expenses | 177.56K | 127.55K | 806.82K | 360.8K | 0 | 0 | 0 | 0 | 10.51M | 0 |
| Operating Income | -34.28M | -76.24M | -83.64M | -94.09M | -111.11M | -124.08M | -301.22M | -267.57M | -143.94M | -112.4M |
| Operating Margin % | -0.85% | -2.16% | -1.98% | -3.09% | -27.02% | -16.74% | -169.72% | -26.07% | -173% | -516.17% |
| Operating Income Growth % | 0.13% | -1.22% | -0.1% | -0.12% | -0.18% | -0.12% | -1.43% | 0.11% | 0.46% | 0.22% |
| EBITDA | -32.37M | -73.15M | -80.17M | -89.09M | -105.59M | -119.45M | -296.49M | -262.08M | -140.44M | -109.27M |
| EBITDA Margin % | -0.8% | -2.07% | -1.9% | -2.92% | -25.68% | -16.12% | -167.06% | -25.54% | -168.79% | -501.8% |
| EBITDA Growth % | 0.15% | -1.26% | -0.1% | -0.11% | -0.19% | -0.13% | -1.48% | 0.12% | 0.46% | 0.22% |
| D&A (Non-Cash Add-back) | 1.92M | 3.09M | 3.47M | 5M | 5.52M | 4.63M | 4.73M | 5.5M | 3.5M | 3.13M |
| EBIT | -35.28M | -77.24M | -88.18M | -94.8M | -112.86M | -154.19M | -301.29M | -276.4M | -133.89M | -107.08M |
| Net Interest Income | 305.07K | 1.26M | 1.81M | 2.26M | -5.34M | -5.39M | 1.43M | 3.53M | 6.91M | 4.59M |
| Interest Income | 305.07K | 1.4M | 1.84M | 2.26M | 2.61M | 3.31M | 3.36M | 4.78M | 8.13M | 4.77M |
| Interest Expense | 0 | 139.25K | 25.93K | 0 | 7.95M | 8.7M | 1.94M | 1.25M | 1.22M | 177.83K |
| Other Income/Expense | 3.08M | 2.5M | -4.56M | -706.88K | -9.7M | -43.39M | -2.44M | -12.24M | 8.82M | 5.14M |
| Pretax Income | -31.2M | -73.74M | -88.21M | -94.8M | -120.81M | -167.47M | -303.66M | -279.82M | -135.12M | -107.25M |
| Pretax Margin % | -0.77% | -2.08% | -2.09% | -3.11% | -29.38% | -22.6% | -171.1% | -27.27% | -162.4% | -492.54% |
| Income Tax | -2.1M | 0 | 0 | 2.17M | -257.33K | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0.94% | 1% | 1% | 1.02% | 0.99% | 0.99% | 1% | 1% | 1% | 1% |
| Net Income | -29.19M | -73.74M | -88.21M | -96.97M | -119.36M | -166.41M | -303.66M | -279.82M | -135.12M | -107.25M |
| Net Margin % | -0.72% | -2.08% | -2.09% | -3.18% | -29.03% | -22.45% | -171.1% | -27.27% | -162.4% | -492.54% |
| Net Income Growth % | 0.19% | -1.53% | -0.2% | -0.1% | -0.23% | -0.39% | -0.82% | 0.08% | 0.52% | 0.21% |
| Net Income (Continuing) | -29.1M | -73.74M | -88.21M | -96.97M | -120.55M | -167.47M | -303.66M | -279.82M | -135.12M | -107.25M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 245.83K | 96.27K | 96.27K | 96.27K | 1.97M | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.43 | -1.01 | -1.08 | -1.05 | -0.97 | -1.07 | -1.42 | -14.07 | -6.09 | -3.95 |
| EPS Growth % | 0.3% | -1.35% | -0.07% | 0.03% | 0.08% | -0.1% | -0.33% | -8.91% | 0.57% | 0.35% |
| EPS (Basic) | -0.43 | -1.01 | -1.08 | -1.05 | -0.97 | -1.07 | -1.42 | -14.07 | -6.09 | -3.95 |
| Diluted Shares Outstanding | 68.37M | 73.21M | 81.92M | 92.54M | 124.62M | 169.87M | 214.62M | 19.89M | 22.17M | 27.16M |
| Basic Shares Outstanding | 68.2M | 73.01M | 81.78M | 92.35M | 124.62M | 165.36M | 214.62M | 19.89M | 22.17M | 27.16M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 171.85M | 124.6M | 138.36M | 87.81M | 94.2M | 471.17M | 448.44M | 315.24M | 153.11M | 97.83M |
| Cash & Short-Term Investments | 162.99M | 104.77M | 127.43M | 81.23M | 89.53M | 411.64M | 401.31M | 253M | 145.29M | 94.11M |
| Cash Only | 57.63M | 19.14M | 23.79M | 23.69M | 22.2M | 250.73M | 71.14M | 46.33M | 14.31M | 65.81M |
| Short-Term Investments | 105.36M | 85.63M | 103.64M | 57.54M | 67.34M | 160.91M | 330.17M | 206.67M | 130.98M | 28.3M |
| Accounts Receivable | 7.33M | 16.57M | 6.49M | 4.05M | 2.03M | 19.06M | 8.03M | 11.74M | 2.41M | 1.2M |
| Days Sales Outstanding | 65.97 | 171 | 56.11 | 48.56 | 180.38 | 938.88 | 1.65K | 417.5 | 1.06K | 2.01K |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 0 | 0 | 0 | 0 | 0 | 0 | 261.19K | 30.38M | 20.43K | 0 |
| Total Non-Current Assets | 41.99M | 49.11M | 48.88M | 43.3M | 49.75M | 68.6M | 47.5M | 33.29M | 17.84M | 15.37M |
| Property, Plant & Equipment | 7.31M | 9.03M | 18.32M | 15.95M | 26.56M | 24.09M | 29.02M | 17.96M | 14.45M | 11.77M |
| Fixed Asset Turnover | 5.55x | 3.92x | 2.30x | 1.91x | 0.15x | 0.31x | 0.06x | 0.57x | 0.06x | 0.02x |
| Goodwill | 10.11M | 10.51M | 10.51M | 10.51M | 10.51M | 10.51M | 10.51M | 10.51M | 0 | 0 |
| Intangible Assets | 3.91M | 7.63M | 6.01M | 4.76M | 3.69M | 3.15M | 2.63M | 2.13M | 0 | 0 |
| Long-Term Investments | 19.99M | 19.83M | 11.39M | 9.41M | 6.32M | 4.89M | 3.91M | 2.01M | 2.78M | 1.61M |
| Other Non-Current Assets | 676.8K | 2.11M | 2.64M | 2.67M | 2.67M | 25.96M | 1.43M | 684.04K | 605.32K | 1.98M |
| Total Assets | 213.84M | 173.71M | 187.24M | 131.11M | 143.95M | 539.77M | 495.94M | 348.53M | 170.95M | 113.2M |
| Asset Turnover | 0.19x | 0.20x | 0.23x | 0.23x | 0.03x | 0.01x | 0.00x | 0.03x | 0.00x | 0.00x |
| Asset Growth % | 0.62% | -0.19% | 0.08% | -0.3% | 0.1% | 2.75% | -0.08% | -0.3% | -0.51% | -0.34% |
| Total Current Liabilities | 31.47M | 43.82M | 35.41M | 35.3M | 31.99M | 41.71M | 65.74M | 96.87M | 42.57M | 35.33M |
| Accounts Payable | 4.46M | 6.99M | 8.49M | 11.02M | 7.65M | 1.47M | 27.97M | 21.08M | 4.65M | 6.44M |
| Days Payables Outstanding | - | - | - | - | - | - | - | - | - | - |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 16.77M | 0 |
| Deferred Revenue (Current) | 1000K | 1000K | 1000K | 257.15K | 124.13K | 46.63K | 21.63K | 0 | 0 | 0 |
| Other Current Liabilities | 5.84M | 8.15M | 9.24M | 14.73M | 15.74M | 20.66M | 20.71M | 15.14M | 9.95M | 23.26M |
| Current Ratio | 5.46x | 2.84x | 3.91x | 2.49x | 2.94x | 11.30x | 6.82x | 3.25x | 3.60x | 2.77x |
| Quick Ratio | 5.46x | 2.84x | 3.91x | 2.49x | 2.94x | 11.30x | 6.82x | 3.25x | 3.60x | 2.77x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 6.44M | 6.51M | 9.35M | 8.78M | 106.56M | 36.93M | 30.53M | 29.3M | 11.03M | 9.37M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 77.02M | 18.66M | 14.96M | 16.61M | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 20.41M | 18.06M | 15.46M | 12.66M | 11.03M | 9.37M |
| Deferred Tax Liabilities | 175.64K | 174.79K | 24.77K | 24.77K | 32.05K | 32.05K | 32.05K | 32.05K | 0 | 0 |
| Other Non-Current Liabilities | 5.49M | 5.93M | 9.1M | 8.61M | 8.99M | 95.16K | 14.83K | 0 | 0 | 0 |
| Total Liabilities | 37.91M | 50.33M | 44.75M | 44.08M | 138.55M | 78.63M | 96.27M | 126.17M | 53.6M | 44.69M |
| Total Debt | 0 | 0 | 0 | 0 | 99.51M | 39.05M | 33.02M | 32.07M | 30.21M | 11.87M |
| Net Debt | -57.63M | -19.14M | -23.79M | -23.69M | 77.31M | -211.68M | -38.12M | -14.25M | 15.9M | -53.95M |
| Debt / Equity | - | - | - | - | 18.41x | 0.08x | 0.08x | 0.14x | 0.26x | 0.17x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest Coverage | - | -547.48x | -3225.35x | - | -13.98x | -14.26x | -155.55x | -213.38x | -117.71x | -632.05x |
| Total Equity | 175.93M | 123.38M | 142.49M | 87.03M | 5.4M | 461.14M | 399.67M | 222.36M | 117.35M | 68.5M |
| Equity Growth % | 0.58% | -0.3% | 0.15% | -0.39% | -0.94% | 84.32% | -0.13% | -0.44% | -0.47% | -0.42% |
| Book Value per Share | 2.57 | 1.69 | 1.74 | 0.94 | 0.04 | 2.71 | 1.86 | 11.18 | 5.29 | 2.52 |
| Total Shareholders' Equity | 175.69M | 123.28M | 142.39M | 86.94M | 3.44M | 461.14M | 399.67M | 222.36M | 117.35M | 68.5M |
| Common Stock | 72.22K | 74.06K | 90.36K | 97.23K | 101.36K | 186.85K | 217.38K | 21.09K | 22.79K | 36.1K |
| Retained Earnings | -361.1M | -434.84M | -523.36M | -620.43M | -739.79M | -906.2M | -1.21B | -1.49B | -1.62B | -1.73B |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 2.71M | 1.33M | -117K | -528.87K | 472.61K | -256.15K | -282.24K | -698.74K | -662.6K | -675.67K |
| Minority Interest | 245.83K | 96.27K | 96.27K | 96.27K | 1.97M | 0 | 0 | 0 | 0 | 0 |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -12.44M | -62.56M | -63.21M | -73.55M | -97.85M | -177.98M | -215.71M | -216.22M | -124.37M | -104.08M |
| Operating CF Margin % | -0.31% | -1.77% | -1.5% | -2.41% | -23.8% | -24.01% | -121.54% | -21.07% | -149.48% | -477.95% |
| Operating CF Growth % | 0.58% | -4.03% | -0.01% | -0.16% | -0.33% | -0.82% | -0.21% | -0% | 0.42% | 0.16% |
| Net Income | -29.1M | -73.74M | -88.21M | -96.97M | -120.55M | -167.47M | -303.66M | -279.82M | -135.12M | -107.25M |
| Depreciation & Amortization | 1.92M | 3.09M | 3.47M | 5M | 5.52M | 4.63M | 4.73M | 5.5M | 3.5M | 3.13M |
| Stock-Based Compensation | 6.19M | 10.48M | 13.07M | 10.65M | 10.9M | 15.65M | 26.34M | 22.56M | 11.07M | 6.6M |
| Deferred Taxes | -2.08M | -849 | -150.03K | 3.42M | -260.82K | 37.93M | 0 | 4.03M | -32.05K | 0 |
| Other Non-Cash Items | -3M | -1.83M | 5.71M | -360.8K | 10.09M | 2.36M | 6.53M | 11.69M | 6.47M | -3.88M |
| Working Capital Changes | 13.64M | -546.16K | 2.9M | 4.71M | -3.54M | -71.07M | 50.35M | 19.83M | -10.26M | -2.66M |
| Change in Receivables | -4.53M | -9.24M | 10.08M | 2.43M | 2.02M | -17.02M | 11.03M | -3.71M | 9.33M | 1.21M |
| Change in Inventory | 1.05M | 592.02K | 531.87K | -963.92K | 935.79K | -55.15M | 0 | 0 | 0 | 0 |
| Change in Payables | 6.59M | 7.28M | 2.68M | 601.26K | -4.59M | 3.25M | 26.14M | 32.61M | -45.99M | -3.37M |
| Cash from Investing | -54.82M | 16.27M | -27.83M | 42.42M | -9.04M | -58.8M | -175.34M | 109.59M | 87.36M | 104.07M |
| Capital Expenditures | -2.78M | -3.94M | -10.29M | -2.09M | -987.93K | -1.52M | -1.23M | -969.15K | -320.9K | 0 |
| CapEx % of Revenue | 0.07% | 0.11% | 0.24% | 0.07% | 0.24% | 0.21% | 0.69% | 0.09% | 0.39% | 2.24% |
| Acquisitions | - | - | - | - | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 1M | 2.2M | 1M | -2.78T | -987.93B | -2.77M | 0 | 0 | 0 | -428.51K |
| Cash from Financing | 84.35M | 7.79M | 95.69M | 31.04M | 105.4M | 465.28M | 211.5M | 81.84M | 5M | 51.48M |
| Debt Issued (Net) | - | - | - | - | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - | - | - | - | - | - |
| Other Financing | 2.45M | 1.49M | 1.34M | 1.81M | -1.14M | 10.62M | 2.06M | -1.11M | -466.65K | 31.86M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | -15.22M | -66.49M | -73.5M | -75.64M | -98.84M | -179.5M | -216.94M | -217.18M | -124.69M | -104.56M |
| FCF Margin % | -0.38% | -1.88% | -1.74% | -2.48% | -24.04% | -24.22% | -122.24% | -21.16% | -149.86% | -480.19% |
| FCF Growth % | 0.51% | -3.37% | -0.11% | -0.03% | -0.31% | -0.82% | -0.21% | -0% | 0.43% | 0.16% |
| FCF per Share | -0.22 | -0.91 | -0.90 | -0.82 | -0.79 | -1.06 | -1.01 | -10.92 | -5.62 | -3.85 |
| FCF Conversion (FCF/Net Income) | 0.43x | 0.85x | 0.72x | 0.76x | 0.82x | 1.07x | 0.71x | 0.77x | 0.92x | 0.97x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 4.62M | 1.08M | 1.07M | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 2.72M | 4.62M | 1.08M | 1.07M | 0 | 0 |
| Metric | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -20.31% | -49.27% | -66.35% | -84.5% | -258.25% | -71.34% | -70.55% | -89.97% | -79.55% | -115.42% |
| Return on Invested Capital (ROIC) | -27.17% | -51.39% | -56.28% | -77.53% | -114.11% | -56.03% | -73.95% | -70.46% | -63.25% | -114.07% |
| Gross Margin | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% |
| Net Margin | -71.94% | -208.49% | -208.92% | -318.12% | -2902.75% | -2245.39% | -17109.87% | -2726.67% | -16239.87% | -49254.27% |
| Debt / Equity | - | - | - | - | 18.41x | 0.08x | 0.08x | 0.14x | 0.26x | 0.17x |
| Interest Coverage | - | -547.48x | -3225.35x | - | -13.98x | -14.26x | -155.55x | -213.38x | -117.71x | -632.05x |
| FCF Conversion | 0.43x | 0.85x | 0.72x | 0.76x | 0.82x | 1.07x | 0.71x | 0.77x | 0.92x | 0.97x |
| Revenue Growth | 288% | -12.83% | 19.37% | -27.8% | -86.51% | 80.24% | -76.05% | 478.23% | -91.89% | -73.83% |
| 2018 | 2019 | 2020 | 2021 | 2024 | |
|---|---|---|---|---|---|
| Reportables | - | - | - | - | 217.76K |
| Reportables Growth | - | - | - | - | - |
| License | 29.86M | 3.64M | 5.17M | 902.26K | - |
| License Growth | - | -87.82% | 42.17% | -82.55% | - |
| Other Revenue | - | - | 786.9K | 627.19K | - |
| Other Revenue Growth | - | - | - | -20.30% | - |
| License with Affiliated Entities | 449.52K | 235.65K | 1.45M | 245.31K | - |
| License with Affiliated Entities Growth | - | -47.58% | 516.90% | -83.13% | - |
| Other Revenue Affiliated Entity | - | - | - | - | - |
| Other Revenue Affiliated Entity Growth | - | - | - | - | - |
| Grant | 171.59K | 237.54K | - | - | - |
| Grant Growth | - | 38.43% | - | - | - |
| Grant with Affiliated Revenue | - | 1.8K | - | - | - |
| Grant with Affiliated Revenue Growth | - | - | - | - | - |
Inovio Pharmaceuticals, Inc. (INO) reported $0.2M in revenue for fiscal year 2024. This represents a 98% decrease from $9.8M in 2011.
Inovio Pharmaceuticals, Inc. (INO) saw revenue decline by 73.8% over the past year.
Inovio Pharmaceuticals, Inc. (INO) reported a net loss of $108.1M for fiscal year 2024.
Inovio Pharmaceuticals, Inc. (INO) has a return on equity (ROE) of -115.4%. Negative ROE indicates the company is unprofitable.
Inovio Pharmaceuticals, Inc. (INO) had negative free cash flow of $20.88B in fiscal year 2024, likely due to heavy capital investments.